StockNow
Log in
U.S. Markets

Roivant (ROIV) announces FDA approval of LISRAYA™ for adults with dermatomyositis; Now available in the US

StockNow breaking-news AI analysis

Roivant subsidiary Priovant published Phase 3 VALOR trial data in JAMA Dermatology demonstrating significant skin improvements and corticosteroid reduction for brepocitinib in adult dermatomyositis patients.

1 stocks
ROIVRoivant Sciences Ltd. Common Shares$36.69Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Any agreements concluded between Iran and Oman are of no importance to us, reports Al Jazeera citing a US source

Fed

Fed's Collins (2028 voter) says recent PCE report did not change modal outlook that current monetary policy is restrictive and will likely lead to a gradual disinflation

Geopolitics

The Trump administration has repeatedly told mediators it has no interest in going back to the terms of the MoU it reached with Iran in June, reports WSJ citing sources